CD274 and non-small cell lung carcinoma: Anti-PD-1/PD-L1 is currently the primary treatment for certain cancers because it is upregulated in various tumors, including melanoma, non-small cell lung cancer, and colorectal cancer, and is involved in tumor immune escape (7–12).